Mixed Connective Tissue Disease (MCTD)

Explore the intricacies of Mixed Connective Tissue Disease (MCTD) in this comprehensive presentation by Prof. Dr. Mike Chan, designed for rheumatologists, immunologists, and integrative medicine specialists. MCTD is a rare autoimmune overlap syndrome that combines features of systemic lupus erythematosus, scleroderma, and polymyositis, with hallmark anti-U1 RNP antibodies. Patients often present with Raynaud’s phenomenon, joint pain, swollen hands, skin changes, muscle weakness, and potential pulmonary or cardiac complications. Diagnosis is based on clinical overlap, serological markers, and exclusion of isolated connective tissue diseases. Conventional management includes corticosteroids and immunosuppressants, but a holistic and regenerative approach strengthens outcomes: Autologous Active Specific Immunotherapy (AASI) to retrain immune tolerance; PSC (Precursor Stem Cells) and GcMAF Forte to restore balanced immunity; Thymus Therapy with MO Thymus and NOP Thymus to reinforce central regulation; and systemic modulators such as Transfer Factors, MO STF, and NOP STF to reduce flares, protect organ systems, and improve long-term quality of life.